Login / Signup

Safety, Tolerability and Pharmacokinetics of Yimitasvir Phosphate Capsule, a Novel Oral Hepatitis C Virus NS5A Inhibitor, in Healthy Chinese Volunteers.

Nan ZhaoRan XieXia ZhaoHong ZhaoBo JiaYingjun ZhangLin LuoZhangma HuangJing LiXingan WangHuan YanBixia HeHongming XieQingyun RenYi Min Cui
Published in: Clinical drug investigation (2019)
This study was registered at the China Food and Drug Administration (Registration numbers: 2014L02064 and 2014L02065) and at http://www.chictr.org.cn (Nos. CTR20140854, CTR20150048 and CTR20150123).
Keyphrases
  • hepatitis c virus
  • drug administration
  • human immunodeficiency virus
  • open label
  • randomized controlled trial
  • dengue virus
  • nitric oxide synthase
  • squamous cell carcinoma
  • clinical trial
  • human health
  • study protocol